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ABSTRACT
Background    Daijokito (DJKT), a classical traditional 
Kampo and Chinese medicine, has been used to treat 
acute pancreatitis in China. In our previous study, 
DJKT was found to reduce the area under the plasma 
concentration-time curve (AUC) of ranitidine in humans. 
Therefore, we established a novel rat model to examine 
the direct absorption of ranitidine after daijokito admin-
istration.
Methods    An in situ intestinal injection with portal 
vein sampling (IIPS) model was created to determine 
the rate of intestinal drug absorption. Rats were divided 
into two groups: the ranitidine group (R, n = 6) or the 
ranitidine and daijokito group (RD, n = 6). Blood was 
collected after intestinal injection of drugs. After the 
experiment, the concentrations of ranitidine were mea-
sured by LC/MS/MS analysis.
Results    The concentrations of ranitidine increased 
linearly with time in both groups.  Compared with the 
R group, the concentrations of ranitidine in RD group 
significantly decreased throughout the experiment.
Conclusion    Co-administration of ranitidine with 
DJKT resulted in significant decreases in intestinal ab-
sorption in rats. The reduction of the systemic ranitidine 
concentration by co-administration of DJKT may be 
due, at least in part, to the inhibition of intestinal absorp-
tion of ranitidine.
Key words    absorption; daijokito; portal vein sampling; 
ranitidine; rat model
Daijokito (DJKT), a classical traditional Kampo and 
Chinese (Da-cheng-qi-tang in Chinese) medicine, has 
been used as a purgative for clearing interior heat and 
excess stomach and intestinal content for 1800 years in 
China. It is composed of daio (Radix et Rhizoma Rhei), 
koboku (Magnolia officinalis Rehd), kijitu (Aurantii 
Fructus Immaturus) and bosho (Natrii Sulfas). Now, 
DJKT is widely used to treat acute pancreatitis in 
China.1 On the other hand, Chinese herbal medicine is 
also co-administered with other Western medicines to 
treat acute pancreatitis such as ranitidine. Ranitidine, 
a H2 receptor antagonist, was used to inhibit gastroin-
testinal and pancreatic secretion, and to protect gastric 
mucosa. Tang WF et al.2 previously reported that the 
concentration of ranitidine was reduced after oral 
administration with DJKT in rats by high-performance 
liquid chromatography (HPLC). In our previous study, 
we found that the plasma concentration of ranitidine was 
reduced by DJKT in humans.3 Therefore, we established 
a novel rat model to examine the direct absorption of 
ranitidine when combined with DJKT. 
 We modified the in situ intestinal perfusion with ve-
nous sampling (IPVS) model for simultaneous profiling 
of intestinal drug absorption and pre-systemic metabo-
lism.4, 5 Compared with HPLC, LC/MS/MS is more ac-
curate, sensitive, rapid and convenient.6 Accordingly, we 
established a novel in situ intestinal injection with portal 
vein sampling (IIPS) rat model to evaluate the effects of 
DJKT on the absorption of ranitidine in rats by LC/MS/
MS analysis.
MATERIALS AND METHODS
Drugs and preparation of perfusion solution
DJKT extract was purchased from Tsumura & Co. 
(Tokyo, Japan). The dosage of DJKT extract was 225 
mg/kg. Ranitidine for treatment was purchased from 
GlaxoSmithKline (Tokyo, Japan). The dosage of 
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ranitidine for rats was 27 mg/kg. Ranitidine solution 
was prepared with saline and diluted to 1.35 mg/mL. 
Ranitidine + DJKT solution was prepared with saline, 
and diluted to 1.35 mg/mL of ranitidine and 10 mg/mL 
of DJKT extract. The solution was vortexed for 10 min. 
Ranitidine hydrochloride for LC/MS/MS analysis was 
purchased from Wako Pure Chemical Industries, Ltd. 
(No.181-01561, Osaka, Japan). 
Animals and surgical procedures
Animal care and anesthesia
The experimental protocol was approved by the ethics 
committee on animal experiments at Tottori University 
(#15-Y-15), and the experiments were carried out in 
accordance with the guidelines for animal experiments 
at the same facility.
 Twelve 10-week-old male Wistar rats (purchased 
from Shimizu Laboratory Supplies Co., Ltd., Kyoto) 
were acclimated in an air-conditioned room at 25 °C 
with 55% humidity, and given standard chow for 4 days 
for adaptation and ad libitum access to water. At the end 
of the fourth day, the rats were randomly divided into 
two groups: the ranitidine group (R, n = 6) or the raniti-
dine and DJKT group (RD, n = 6) (body weight, 272.53 
± 6.79 g and 274.32 ± 6.29 g, respectively). The rats were 
fasted 12 hours before the experiment.
 Rats were anesthetized with pentobarbital sodium 
(50 mg/kg) by peritoneal injection, and then placed in 
a warm jacket circulated with warm (38 °C) water and 
under a heating lamp to maintain body temperature 
during the experiment. O2 was also supplied over the 
head of the rat during the experiment. To maintain anes-
thesia during the course, one-third of the initial dose of 
pentobarbital sodium was administered throughout the 
remainder of the experiment.
Surgical procedures of in situ intestinal injection with 
portal vein sampling (IIPS)
The surgical procedures were adapted from previous 
reports with some modifications to prepare the perfused 
rat intestine for venous sampling.4, 5, 7–9 First, the rat was 
intraperitoneally injected with 1 mL of heparin. The ab-
domen of the anesthetized animal was shaved, and a lon-
gitudinal midline incision of 5 cm was carefully made 
to expose the small intestine and the portal vein. A 22-G 
catheter (No.SR-OT2232C, Terumo Corporation, Tokyo, 
Japan) was used without the catheter hub to reduce the 
dead space for blood sampling. A catheter filled with 
heparinized saline was inserted into the portal vein and 
secured with instant glue to avoid obstruction of portal 
venous flow into the liver. The original inner cylinder 
was replaced with a plugged one inside the catheter 
to prevent blood overflow. For intestinal perfusion, an 
intestinal segment 5 cm under the pylorus was selected 
and ligated with 1–0 sutures. Next, the drug solution was 
injected into the intestine using a 10-mL syringe from 
6 cm under the pylorus. Rats in group R were injected 
with ranitidine solution and those in group RD were 
injected with ranitidine + DJKT solution. The injection 
flow rate was 1 mL/min, and the start time of injection 
was recorded. The inner plugged cylinder of the catheter 
was removed to collect blood 10 min later, and then rein-
serted to stop blood flow after 0.3–0.4 mL of blood was 
collected. Subsequently, blood was collected another 3 
times at 20, 30 and 40 min. During the experiment, the 
exposed intestinal segment was kept moist by covering it 
with a piece of sterilized gauze wetted with saline, and 
warm isotonic saline was sprinkled on the gauze many 
times by a syringe. At the termination of the experiment, 
systemic blood was collected from the heart, and rats 
were sacrificed by aortic bleeding.
LC/MS/MS Analysis
Sample preparation
The blood sample was centrifuged (2,500 rpm, 15 min, 
4 °C), and the supernatant of plasma was collected and 
stored at –80 °C. Subsequently, 100 μL of plasma was 
mixed with 300 μL of 100% methanol. The solution 
was vortexed at 4 °C, and then collected by centrifuging 
(15,000 rpm, 17 min, 4 °C). Next, 100 μL of supernatant 
was placed into a tube for analysis. 
Preparation of standard solution
Ranitidine was weighed and dissolved in 7.5% metha-
nol. The concentration of ranitidine was 1 mg/mL. The 
solution was then diluted to 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 
50, 100, 500 or 1,000 ng/mL, and placed into tubes for 
analysis.
Sample analysis
The concentration of ranitidine in the plasma was ana-
lyzed using Prominence ultra fast liquid chromatography 
(Shimadzu, Kyoto) coupled with tandem mass spec-
trometry (LC/MS/MS) method (QTRAP 5500, SCIEX, 
Tokyo). Ten µL of each sample was injected. Data 
acquisition and analysis were performed by Analyst 1.5 
software (SCIEX, MA).
RESULTS
Calibration curves for ranitidine
The linear range of ranitidine obtained using the select-
ed internal standards is shown in Fig. 1. The regression 
equation was established by the ratio of analyte peak 
area (counts) to analyte concentration. The “linear” re-
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gression equation (“1/X” weighted) of y = 6.28e + 005x 
+ 2.26e + 004 (r = 0.9990, where x is the concentration 
of analyte and y is the peak area) was obtained.
Concentration of ranitidine
The concentration of ranitidine is described in Fig. 2 
and Fig. 3. The plasma concentrations of ranitidine 
increased linearly with time in both groups (Fig. 3). In 
group R, the ranitidine concentrations at 10, 20, 30 and 
40 min after intestinal injection were 0.17 ± 0.06, 0.26 
± 0.03, 0.42 ± 0.06 and 0.65 ± 0.08 ng/mL, respectively, 
whereas in group RD, the ranitidine concentrations at 
10, 20, 30 and 40 min were 0.11 ± 0.02, 0.15 ± 0.04, 0.20 
± 0.05 and 0.33 ± 0.05 ng/mL, respectively. Compared 
with ranitidine alone (group R), the concentrations of 
ranitidine after co-administration with DJKT (group 
RD) were significantly lower (P < 0.05). 
DISCUSSION
In this study, the ranitidine concentration in the portal 
vein in the IIPS rat model was successfully measured af-
ter intestinal injection. Compared with the conventional 
rat model by oral administration, the IIPS model demon-
strated more direct absorption of the medicine. The 
intestines as the main organ of absorption play a key role 
in pharmacokinetics. Therefore, intestinal injection is a 
Fig. 1.  
Fig. 1. Relationship between ranitidine concentration and peak area. The linear range of ranitidine is shown.  Concentrations of 0.01, 0.05, 
0.1, 0.5, 1, 5, 10, 50, 100, 500 and 1000 ng/mL of ranitidine were measured using the LC/MS/MS approach as internal standards. LC/
MS/MS, liquid chromatography/mass spectrometry/mass spectrometry.
more direct, reliable and effective way to examine the 
pharmacokinetics of medicine than oral administration 
in animal studies.
 Experimental techniques for evaluating the absorp-
tion of drugs include the use of isolated cells, everted 
gut sac (EGS) and in situ single-pass intestinal perfusion 
(SPIP).4 However, morphological damage to intestinal 
tissue due to everting and the lack of intact vascular 
supply are disadvantages of the EGS model.10 Recently, 
Li et al.4 reported the superiority of intestinal perfusion 
with venous sampling (IPVS) to EGS and SPIP as meth-
ods to study drug absorption. Cummins et al.9 examined 
the modulation of P-glycoprotein in the intestinal drug 
metabolism by cytochrome P450 3A4 using IPVS, and 
reported the advantages of IPVS for studies on intestinal 
drug absorption.
 However, for IPVS, a total of 50–70 mL of blood 
drawn from some donor rats needs to be prepared to be 
transfused into the recipient rat through the jugular vein 
to replace the blood lost via the mesenteric or portal 
vein.7, 9, 10 On the other hand, with our IIPS method, no 
donor rats are needed due to the minimal blood loss. 
This is an advantage of IIPS over IPVS to reduce the 
number of sacrificed animals.
 Now, DJKT is widely used to treat acute pancreatitis 
in China.1 Moreover, Chinese herbal medicines are 
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Fig. 2. LC/MS/MS analysis of ranitidine. Representative raw data for LC/MS/MS analysis are shown. A) – D): group R, E) – H): group 
RD. A) at 10 min. Area: 1.47e + 005 counts, Height: 1.42e + 004 cps RT: 2.78 min; B) at 20 min. Area: 2.01e + 005 counts, Height: 1.98e 
+ 004 cps RT: 2.77 min; C) at 30 min. Area: 3.31e + 005 counts, Height: 3.35e + 004 cps RT: 3.07 min; D) at 40 min. Area: 4.60e + 005 
counts, Height: 4.49e + 004 cps RT: 2.78 min; E) at 10 min. Area: 8.11e + 004 counts, Height: 7.89e + 003 cps RT: 2.78 min; F) at 20 min. 
Area: 1.21e + 005 counts, Height: 1.17e + 004 cps RT: 2.79 min; G) at 30 min. Area: 1.60e + 005 counts, Height: 1.56e + 004 cps RT: 2.72 
min; H) at 40 min. Area: 1.97e + 005 counts, Height: 1.82e + 004 cps RT: 2.77 min. LC/MS/MS, liquid chromatography/mass spectrom-
etry/mass spectrometry. Area indicates the area counts of peaks on the ion chromatogram, and height indicates the peak height (cps). RT 
indicates the retention time.  The area was converted into the concentration of ranitidine by calculation.Group R received ranitidine alone. 
Group RD received ranitidine with Daijokito.
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MS/MS analysis is a direct, reliable and effective way to 
study the pharmacokinetics of drugs. Co-administration 
of ranitidine with DJKT resulted in significantly de-
creased absorption of ranitidine in rats. Therefore, we 
speculate that DJKT reduces the systemic ranitidine lev-
els, at least in part, by inhibiting the intestinal absorption 
of ranitidine. Thus, the co-administration of ranitidine 
and DJKT should be avoided in clinical settings.
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Fig. 3. Plasma concentration-time curves for ranitidine. Filled 
circles with black lines represent the concentration-time curve for 
ranitidine in portal venous plasma in group R, and open circles 
with gray lines represent the curve in group RD. The vertical line 
indicates the concentration of ranitidine and the horizontal line 
indicates the time after injection of drugs into the intestine. *P < 
0.05 vs. group R. Group R received ranitidine alone (R). Group 
RD received ranitidine with Daijokito (RD).
usually co-administered with other Western medicines 
during the treatment of many diseases. Ranitidine, a H2 
receptor antagonist, is used to inhibit gastrointestinal and 
pancreatic secretion, and to protect the gastric mucosa. 
We previously reported that the area under the plasma 
concentration-time curve (AUC) of ranitidine was 
reduced by DJKT in humans.3 In the present study, al-
though the dose of ranitidine in both groups was 27 mg/
kg, the rate of increase in the concentration of ranitidine 
greatly differed between the groups. This difference in 
concentration in the portal vein demonstrates the direct 
effects of DJKT on intestinal absorption of ranitidine. 
These results suggest that the reduction of the systemic 
concentration of ranitidine by co-administration of DJKT 
is due, at least in part, to the inhibition of intestinal ab-
sorption of ranitidine. 
 In our previous report, we speculated the mecha-
nism underlying the inhibitory effect of DJKT on ranit-
idine AUC as a reduction of absorption, and discussed 
about some elements concerning to drug absorption such 
as changes in gastric emptying rate, intestinal motility, 
activities of P-glycoprotein and CYP3A4. The direct 
intestinal injection of drugs applied in this study may 
exclude a gastric role in reduced absorption. Ranitidine 
and DJKT were injected simultaneously into intestine, 
so P-glycoprotein activation and/or increased motility of 
intestine by DJKT are quite unlikely to be simple mech-
anisms, because onset of reduction of ranitidine concen-
tration was so rapid. The precise mechanism underlying 
the inhibitory effects on absorption are still unclear and 
further studies should be performed.
 In conclusion, the novel IIPS rat model with LC/
